Research Paper

Risk of Stroke in Migraineurs Using Triptans. Associations with Age, Sex, Stroke Severity and Subtype

Vanna Albieri a, Tom Skyhøj Olsen b,*, Klaus Kaæe Andersen a

a Statistics, Bioinformatics and Registry, Danish Cancer Society Research Center, 2100 Copenhagen, Denmark
b Department of Neurology, Bispebjerg University Hospital, 2400 Copenhagen, Denmark

1. Introduction

Migraine is associated with a two-fold increased relative risk for stroke (Eminan et al., 2005; Schurks et al., 2009; Spector et al., 2010). Etiology of stroke in migraine remains still obscure (Kurth and Diener, 2012). It is not known whether it is thromboembolic or migraine-specific being different from that of thromboembolism (Kurth and Diener, 2012). Studies relate migraine to hemorrhagic stroke but they are too few and too small to make conclusions about etiology (Sacco et al., 2013; Kurth and Tzourio, 2013).

The reason for our insufficient knowledge on stroke in migraineurs is in part that the increased risk in absolute terms is small and available studies on the risk for stroke among migraineurs are hampered by small numbers weakening the reliability of risk estimations (Kurth and Diener, 2012).

As an alternative way of establishing a sizeable cohort of migraine patients with stroke we identified migraine through triptan utilization. Based on this cohort the purpose of this study was to estimate risk of stroke and to characterize strokes by age, sex, subtype and severity in the population of Danes with migraine who had been prescribed triptans.

2. Methods

The design of this study was based on the idea of establishing a large cohort of migraine patients identified by triptan utilization. The study is a cohort study on all Danes aged 25–80 years who lived in Denmark during some or all of the period between January 1, 2003 and December 31, 2011. The cohort was linked to the Danish registries. In Denmark triptans need prescription by a physician. Information on hospitalization for stroke was obtained from the Danish Register of Causes of Death, Danish Cancer Registry, Danish National Registry of Patients, Danish National Registry of Hospital Discharges, Danish National Registries of Medical Devices, Danish National Prescription Registry, Danish National Prescription Registry for Catastrophically Ill and Psychotherapy Registries. Information on stroke severity/subtype and cardiovascular risk factors was available for stroke patients. Information on stroke severity/subtype and cardiovascular risk factors was available for stroke patients. Findings: Of the 49,711 patients hospitalized for a first stroke, 1084 were migraineurs using triptans. Adjusting for age, sex, income, and educational level, risk for stroke was higher among migraineurs in respect to all strokes (RR 1.07; CI 1.01–1.14) and ischemic strokes (RR 1.07; CI 1.00–1.14). Risk for hemorrhagic stroke was increased but only in women (RR 1.41; CI 1.11–1.79), Risk was for mild strokes (RR 1.31; CI 1.16–1.48) while risk for severe strokes was lower among migraineurs (RR 0.77; CI 0.65–0.91). Risk was age-related; highest among women 25–45 years (RR = 1.7). Risk was unrelated to numbers of dispensations. Interpretation: Migraineurs identified by triptan utilization had higher risk for stroke. Strokes were minor and cardiovascular risk factors were less prevalent pointing to a migraine-specific etiology of stroke different from that of thromboembolism.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
of the WHO Task Force on Stroke and other Cerebrovascular Disorders, 1989) and we included incident hospital admissions for first-ever stroke (ischemic or hemorrhagic; ICD-10 codes I61 and I63) in the period 2003–2011. For patients with multiple hospital admissions, only the first admission was included. Transient ischemic attacks were not included in the Registry. Patients aged <25 and >80 years were excluded from the study, as well as patients for whom scanning was not performed (0.4% result not available (0.7%). Most stroke patients (90%) are admitted to hospital, as access to hospital care is free in Denmark (Jørgensen et al., 1992). Information on education and disposable income for the cohort was obtained from Statistics Denmark (Dalton et al., 2008): both variables are associated with incidence of stroke and to some level proxies for lifestyle factors such as smoking (Dalton et al., 2008). Education was grouped into three categories: basic/high school (7–12 years of primary, secondary, and grammar-school education); vocational (10–12 years of education including vocational training); and higher (≥13 years of education) (Dalton et al., 2008). People for whom information on education was missing were excluded (14%). Disposable income was defined as household income after taxation and interest per person, adjusted for the number of people in the household and deflated according to the 2000 value of the Danish crown (DKK). For the analyses, disposable income was categorized into the 20th, 40th, 60th, and 80th percentiles of the age and gender-specific income distribution.

To study the association between migraine (identified through triptan utilization) and the risk factor profile among stroke patients, we included information from Danish Stroke Registry. These data include age, sex, stroke severity on admission measured on the Scandinavian stroke scale (Lindenstrøm et al., 1991), stroke subtype (ischemic/hemorrhagic) and cardiovascular profile. The Scandinavian stroke scale is a validated neurological scale of stroke severity from 0 to 58, lower scores indicating more severe strokes (Lindenstrøm et al., 1991). Ischemic stroke was distinguished from hemorrhagic stroke by computed tomography or magnetic resonance scanning. The cardiovascular profile (only available for the stroke patients) included information on alcohol consumption under/over the limit set by the Danish National Board of Health) and current daily smoking. Diabetes mellitus, atrial fibrillation (chronic or paroxysmic), arterial hypertension, previous myocardial infarction, previous stroke, and intermittent arterial claudication were diagnosed according to current Danish standards (Mainz et al., 2004).

The study protocol was approved by the board of the Danish Stroke Registry and the Danish Data Protection Agency (journal number 2012-41-0719).

2.1. Statistics

We conducted a prospective analysis of the entire Danish population aged 25–80 in the period 2003–2011 and estimated the association between migraine identified through triptan utilization and risk of hospitalization for stroke. The cohort was tabulated in grouped-data format, with one stratum for each combination of the available covariates (i.e., sex, age, calendar year, education, disposable income, and triptan use). Each stratum provided information on alcohol consumption (under/over the limit set by the Danish National Board of Health) and current daily smoking. Diabetes mellitus, atrial fibrillation (chronic or paroxysmic), arterial hypertension, previous myocardial infarction, previous stroke, and intermittent arterial claudication were diagnosed according to current Danish standards (Mainz et al., 2004).

The participants contributed 32.923 million person–years to the analysis; of these, triptan-users contributed 1.105 million person–years. During the study period, 49,711 Danes aged 25–80 years were registered in the Danish Stroke Register as having been hospitalized for a first stroke. Among these, 1084 had been prescribed triptans within the past five-years prior to index date. The mean number of prescriptions dispensed during five years was 22 packages (inter quartile range [IQR] 24 packages; 1st quartile: 4 packages; 3rd quartile 28 packages).

Demographic data for users and non-users of triptans are presented in Table 1. Triptan users were younger, more often women, and more often belonged to low-income and short-education groups. The crude incidence of hospitalization for stroke was 1.51 per 1000 per year for non-users of triptans and 1.36 per 1000 per year for users.

The relation between age, sex and use of triptans is illustrated in Fig. 1. Triptans were prescribed to 5% of women and 1.4% of men aged 25–80 years during the study period. Usage reached a maximum at the age of 45–50 years (7.5% of women and 1.8% of men) and decreased rapidly with age after the end of the fifties.

The relative risks for stroke among migraine patients identified through triptan utilization are shown in Table 2. The risk was increased for all strokes (RR 1.07; CI 1.01–1.14) and ischemic strokes (RR 1.07; CI 1.00–1.14) while not for hemorrhagic strokes (RR 1.18; CI 0.95–1.45). Stratifying by sex the risk for all stroke and ischemic stroke was increased in both sexes. There was an increased risk for hemorrhagic stroke in women (RR 1.41; CI 1.11–1.80) but not in men. Test for effect modification in risk of stroke with respect to triptan use for ischemic versus hemorrhagic stroke showed no statistical significant difference (Table 2).

Overall the risk for severe stroke was lower among migraine patients identified through triptan utilization (RR 0.71; CI 0.65–0.91), while the risk for mild stroke was higher (RR 1.31; CI 1.16–1.48). The relation between risk for stroke by age in migraine patients identified through triptan use is shown in Fig. 2. The estimated risk was closely associated with
age and was highest among women aged 25–45 years (RR ≈ 1.7), decreasing rapidly thereafter with no association with triptan use after the age of about 55 years.

As a sensitivity analysis we examined the effect of triptan use within one-year, two-years, three-years, and four-years time window prior to index data. We found virtually no difference in effect estimates between the analysis defining exposure in one and five years’ time. Also the additional categorization for triptan use (no use, use of one package, and use of two and more packages) did not show different results in respect to the main analysis. We examined the dose response effect by including the number of prescriptions as a continuous variable along with the indicator of triptan use. This parametrization of the model allowed for estimation of RR per prescription within triptan users. Overall, we find the RR pertinent to the dose response relationship to be 0–99 (CI 0.98–1.01) in women and 1.00 (CI 0.99–1.01) in men. Thus, we did not find evidence of a dose response relationship between number of prescriptions for triptans on the risk of stroke, i.e. the RR associated with ever/never use remained unchanged.

The cardiovascular risk factor profile of stroke patients stratified by triptan use is shown in Table 3. Table 4 shows the age-adjusted prevalence of cardiovascular risk factors in stroke patients stratified by use of triptans. The prevalence of cardiovascular risk factors was lower among stroke patients with migraine identified through triptan utilization.

There was no effect modification of oral contraceptive (OC) use on the effect of triptans in subanalysis including women between 25 and 50 years of age: 5.27% of women used triptans while using OC at the same time compared to 5.44% using triptans while not using OC at the same time. Running our model without adjusting for oral contraceptives use risk of stroke among triptan users 25–50 years of age was HR 1.41 (CI 1.27–1.65); adjusting for oral contraceptives risk of stroke among triptan users was HR 1.43 (CI 1.25–1.63).

4. Discussion

In this study of the Danish population during nine years of follow-up, based on the concept of identifying migraine through triptan utilization the risk of being hospitalized for stroke was higher among migraineurs. The strokes of Table 1

|                      | Non-users | Users |
|----------------------|-----------|-------|
|                      | %a 10^3 person-years | No. of events | Incidence 10^2 person-years | %a 10^3 person-years | No. of events | Incidence 10^2 person-years |
| All                  | All       |       |             | All       |       |             |
| Sex                  |           |       |             |           |       |             |
| Female               | 49.23     | 156.67| 19,951      | 1.20      |       |             |
| Male                 | 50.77     | 161.51| 28,676      | 1.84      |       |             |
| Income (quintile)    |           |       |             |           |       |             |
| 1st                  | 19.9      | 63.29 | 11,594      | 1.84      |       |             |
| 2nd                  | 20.04     | 63.75 | 11,083      | 1.72      |       |             |
| 3rd                  | 20.04     | 63.78 | 9754        | 1.51      |       |             |
| 4th                  | 20.03     | 63.75 | 8053        | 1.34      |       |             |
| 5th                  | 19.99     | 63.64 | 7543        | 1.17      |       |             |
| Education            |           |       |             |           |       |             |
| Basic                | 10.74     | 34.20 | 1797        | 1.53      |       |             |
| Vocational           | 61.08     | 194.28| 38,468      | 1.17      |       |             |
| Higher               | 25.56     | 81.43 | 7178        | 1.63      |       |             |
| Unknown              | 2.62      | 8.33  | 1184        | 1.58      |       |             |
| Age (years)          |           |       |             |           |       |             |
| ≤35                  | 20.79     | 66.30 | 598         | 0.09      |       |             |
| 36–47                | 26.07     | 83.10 | 3110        | 0.37      |       |             |
| 48–61                | 27.98     | 89.08 | 12,223      | 1.37      |       |             |
| ≥62                  | 25.16     | 79.70 | 32,696      | 4.10      |       |             |

a Percentages of non-users and users of triptan in the total population.
b Age-adjusted incidence with direct standardization by use of the whole Danish cohort as the reference population.

Fig. 1. Percentages of triptan users by attained age and calendar year in the Danish population aged 25–80 years in the period 2003–2011; (a) males, (b) females.
migraineurs identified through triptan utilization were typically minor strokes while severe strokes were less prevalent.

### 4.1. Stroke Risk Factor Profile

The prevalence of risk factors for stroke among stroke patients who used triptans was markedly lower than among stroke patients who did not use triptans. This might reflect caution by Danish doctors in prescribing triptans for patients with cardiovascular risk factors. The fact that patients with risk factors nevertheless received prescriptions for triptans may indicate a risk–benefit decision. Alternatively, the etiology of strokes in triptan users may differ from that of non-users (with a different risk factor profile) which might suggest a different kind of stroke etiology for triptan users i.e. migraineurs. We had information on the cardiovascular risk factor profiles only for those with stroke; however, the markedly lower age-adjusted prevalence in users of triptans speaks against a higher prevalence of cardiovascular risk factors as the underlying cause of the increased risk for stroke of triptan users. Use of contraceptive pills was the same in users and non-users of triptans and did not influence the effect of triptans. Furthermore, the risk for stroke among triptan users was increased for both sexes.

### 4.2. Cause of Stroke: Triptans vs Migraine

In Denmark, triptans are registered only for the treatment of migraine and cluster headache. As the prevalence of cluster headache is considerably lower than that of migraine, particularly among women (Manzoni and Stovner, 2010), our population of triptan users can be considered as a group of patients with migraine. We found that risk of stroke among triptan users was unrelated to numbers of prescriptions dispensed. Reports on strokes directly related to intake of triptans are rare (Roberto et al., 2015). Thus, overrepresentation of stroke in triptan users in our study seems more likely to be the result of the underlying migraine disorder rather than use of triptans. As a result of the vasoconstricting effect of triptans the question of a possible association between the use of triptans and stroke comes up regularly since the number of users is high (5% of Danish women between 25 and 80 years; 7.5% of Danish women aged 45–50 years). Although the
Prevalence (%) of risk factors with respect to triptan use adjusted by age (overall and by sex) for patients with stroke.

Table 4

| Risk factor                  | All Non-users (%) | All Users (%) | Men Non-users (%) | Men Users (%) | Women Non-users (%) | Women Users (%) |
|------------------------------|-------------------|---------------|-------------------|--------------|---------------------|-----------------|
| **Alcohol**                  |                   |               |                   |              |                     |                 |
| ≤14/21 drinks per week       | 38,302 (78.76)    | 942 (89.60)   | 21,846 (76.18)    | 276 (84.15)  | 16456 (82.47)       | 666 (88.10)     |
| >14/21 drinks per week       | 4965 (10.21)      | 47 (4.34)     | 4000 (13.95)      | 23 (7.01)    | 965 (4.84)          | 24 (3.17)       |
| Missing data                 | 5362 (11.03)      | 95 (8.76)     | 2830 (9.87)       | 29 (8.84)    | 2532 (12.69)        | 66 (8.73)       |
| **Smoking**                  |                   |               |                   |              |                     |                 |
| Daily smokers                | 19,502 (40.10)    | 395 (36.44)   | 12,101 (42.20)    | 133 (40.55)  | 7401 (38.09)        | 262 (34.66)     |
| Occasionally smokers         | 591 (1.22)        | 15 (1.38)     | 369 (1.29)        | 7 (2.13)     | 222 (1.11)          | 8 (1.06)        |
| Former smokers               | 9664 (19.87)      | 181 (16.70)   | 6566 (22.99)      | 59 (17.99)   | 3098 (15.53)        | 122 (16.14)     |
| Never smokers                | 13,065 (26.87)    | 374 (34.50)   | 6528 (22.76)      | 97 (29.57)   | 6537 (32.76)        | 277 (36.64)     |
| Missing data                 | 5807 (11.94)      | 119 (10.98)   | 3112 (10.85)      | 32 (9.76)    | 2695 (13.51)        | 87 (11.51)      |
| **Diabetes**                 |                   |               |                   |              |                     |                 |
| Yes                          | 6329 (13.01)      | 75 (6.92)     | 4091 (14.27)      | 25 (7.62)    | 2238 (11.22)        | 50 (6.61)       |
| No                           | 41,510 (85.36)    | 997 (91.97)   | 24,120 (84.11)    | 298 (80.85)  | 15,963 (80)         | 699 (92.46)     |
| Missing data                 | 790 (1.62)        | 12 (1.11)     | 465 (1.62)        | 5 (1.52)     | 325 (1.63)          | 7 (0.93)        |
| **Atrial fibrillation**      |                   |               |                   |              |                     |                 |
| Yes                          | 5157 (10.60)      | 68 (6.27)     | 3013 (10.51)      | 21 (6.4)     | 1404 (7.05)         | 47 (6.22)       |
| No                           | 42,493 (87.38)    | 1000 (92.25)  | 25,081 (87.46)    | 300 (91.46)  | 17,412 (87.27)      | 700 (92.59)     |
| Missing data                 | 973 (2.01)        | 16 (1.48)     | 582 (2.03)        | 7 (2.13)     | 397 (1.99)          | 9 (1.19)        |
| **Hypertension**             |                   |               |                   |              |                     |                 |
| Yes                          | 22,509 (46.29)    | 433 (39.94)   | 13,119 (45.75)    | 131 (39.49)  | 9390 (47.06)        | 302 (39.95)     |
| No                           | 42,832 (87.08)    | 1000 (92.25)  | 25,081 (87.46)    | 300 (91.46)  | 17,412 (87.27)      | 700 (92.59)     |
| Missing data                 | 973 (2.01)        | 16 (1.48)     | 582 (2.03)        | 7 (2.13)     | 397 (1.99)          | 9 (1.19)        |
| **Prev. myocardial infarct** |                   |               |                   |              |                     |                 |
| Yes                          | 1383 (2.84)       | 30 (2.77)     | 846 (2.95)        | 11 (3.35)    | 537 (2.69)          | 19 (2.51)       |
| No                           | 38,696 (80.93)    | 899 (82.93)   | 22,786 (79.5)     | 277 (84.45)  | 15,963 (80)         | 622 (82.28)     |
| Missing data                 | 8551 (17.58)      | 172 (15.87)   | 5027 (17.53)      | 46 (14.02)   | 3524 (17.66)        | 126 (16.67)     |
| **Total**                    | 48,629            | 1084          | 28,676            | 328          | 19,953              | 756             |

* The maximum limit set by the Danish National Board of Health: 14 drinks per week for women and 21 for men.
stroke is present only when migraine is associated with aura (Schurks et al., 2009). Studies of brain blood flow during migraine auras have shown focal reduction of cerebral blood flow consistent with ischemia (Olsen et al., 1987; Olsen and Lassen, 1989). Thus, migraine patients with aura may develop ischemia at the microvascular level, which, under some conditions, manifests as a minor stroke. The design of our study did not allow us to distinguish between migraine with and without aura; we were therefore unable to determine whether the increased risk of migraine patients for stroke is associated with both types of migraine or only with migraine with aura. The increased risk for hemorrhagic stroke among migraineurs using triptans in this study and in other studies on migraine and stroke remains to be explained (Kurth and Tzourio, 2013). Suggestions such as altered platelet or endothelial function, use of non-steroidal anti-inflammatory drugs for migraine attacks and structural brain lesions or malformations giving rise to headache mimicking migraine are still hypothetical (Sacco et al., 2013).

4.4. Strengths and Limitations

A major strength of this study was the large dataset, with information on age, sex, disposable income, and length of education for the entire Danish population (5.5 million). Furthermore, the personal identification number allowed linkage to the Danish Registry of Prescriptions and to the Danish Stroke Registry, which covers patients hospitalized for stroke in Denmark since 2003. The hospitalization rate according to the registry is high (2.3 per 1000/year) (Andersen et al., 2014) and registration in the Registry has high validity (Wildenschild et al., 2013). The completeness of the data on diabetes, previous myocardial infarction, atrial fibrillation, and hypertension for patients registered with a stroke in this register was >87%; for alcohol consumption, smoking, and intermittent claudication completeness was >83%. Information on stroke severity on hospital admission was available for 80% of patients. Therefore, we consider that our study population was representative of both the Danish population of migraineurs prescribed triptans and the Danish population hospitalized for stroke.

A weakness of the study was the lack of information on headache and migraine type nor did we have exact information on the predictive value of using triptan utilization as a proxy for migraine. However, as triptans are licensed in Denmark only for migraine (and cluster headache, as discussed above) and need prescription by an authorized physician, we consider it highly likely that the population with prescriptions for triptans represents a migraine population. The population without prescriptions for triptans includes patients with migraine not using triptans. If, as previously mentioned, the increased risk for stroke in triptan users reflects an increased risk for stroke among patients with migraine, the risk estimates in our study would be biased towards the null.

Users and non-users of triptans may differ according to use of concomitant analgesic agents such as aspirin, paracetamol and NSAID’s (non-steroidal anti-inflammatory drugs). As a number of these drugs are delivered over-the-counter they cannot be tracked in the register of prescriptions and cannot be adjusted for in our model. Paracetamol does not influence risk of stroke (García-Poza et al., 2015). Aspirin lowers risk of ischemic stroke but may increase risk of hemorrhagic stroke (Gorelick and Weisman, 2005). While some of the NSAID’s appear to increase the risk of stroke, NSAID’s as a group do not increase significantly the risk for stroke (García-Poza et al., 2015; Coxib and traditional NSAID Trials’ (CNT) Collaboration, 2013). So even if an effect of these drugs cannot be excluded it will hardly be of a magnitude that it is going to change our conclusions especially regarding ischemic stroke. As >90% of patients with acute stroke are hospitalized in Denmark (Jørgensen et al., 1992), our observations apply to the majority of stroke patients but only to those who are hospitalized. The Danish Stroke Registry does not include transient ischemic attacks. As the risk of migraineurs prescribed triptans in our study was for minor stroke, inclusion of transient ischemic attacks in the analysis would have been desirable. As another proxy for migraine usage of ergotamine was considered. However, the use of ergotamine in Denmark is so small (0.15% of all Danes have used ergotamine within a 5-year period compared to approx. 4.6% for triptans (i.e. 30 times more frequent)) that it does not serve as a valid comparison.

5. In Conclusion

Migraineurs using triptans are at increased risk for both ischemic and hemorrhagic stroke. The excess risk did not seem to be related to the use of triptans as such; instead, our study points to the underlying migraine disease as the cause of the increased risk of stroke among migraineurs. Strokes in migraineurs differed from those of the general stroke population by being less severe and associated with lower prevalence of cardiovascular risk factors. Thus, our study suggests an etiology of stroke in migraineurs different from that of atherosclerotic thromboembolism, probably at the microvascular level. Whatever the cause, stroke is a serious incident in young people undergoing treatment for a disorder that is usually not perceived dangerous. Therefore, our study underlines the necessity of making a careful risk assessment before prescribing triptans for the treatment of headaches. If, as indicated in this study, migraine is associated with an etiology of stroke different from thromboembolism this may have clinical implications for this (although smaller) part of the stroke population in regard to both acute treatment (thrombolitics) and secondary prevention (platelet aggregation inhibitors, statins). More studies are warranted.

Declaration of Interests

The authors have nothing to disclose.

Funding

The Helge Peetz og Verner Peetz og hustru Vilma Peetz Foundation (grant no.: 1-24-12-2013).

The authors have not been paid to write this article.

The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Authors’ Contributions

Study concept and design: All authors.

Acquisition, analysis and interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript: All authors.

Statistical analysis: Alberi, Andersen.

Obtained funding: Andersen, Olsen.

Study supervision: Andersen, Olsen.

Role of the Funding Source

The funder had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

References

Andersen, K.K., Steding-Jessen, M., Dalton, S.D., Olsen, T.S., 2014. Socioeconomic position and incidence of ischemic stroke in Denmark 2003–2012. A nationwide hospital-based study. J. Am. Heart Assoc. 3, e000762.

Cole, S., Hernán, M.A., 2004. Adjusted survival curves with inverse probability weights. Comput. Methods Prog. Biomed. 75, 45–49.

Coxib and traditional NSAID Trials’ (CNT) Collaboration, 2013. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769–779.

Dalton, S.D., Steding-Jessen, M., Gulbin, M., Frederiksen, K., Engholm, G., Schuz, J., 2008. Social inequality and incidence of and survival from cancer in a population-based study in Denmark, 1994–2003: background, aims, material and methods. Eur. J. Cancer 44, 1938–1949.
